
Fubo TV reported a fourth-quarter increase in subscribers and revenue, ending the period with 1.67 million paid subscribers in North America, up from 1.613 million in the third quarter and 1.45 million in the second quarter. The company's total revenue for the quarter reached $433.8 million, an 8% increase from $410 million in Q4 2023, driven by a rise in subscription revenue to $406.8 million, despite a drop in advertising revenue to $34.3 million. Fubo TV's net loss from continuing operations narrowed to $40.9 million from $71 million a year earlier, with an adjusted EPS loss of 2 cents, improved from an 18 cents loss in the prior year. Despite the positive quarterly results, Fubo TV anticipates a decline in subscribers in the first quarter of 2025, projecting a subscriber count between 1.43 million and 1.46 million. This forecast led to a significant drop in the company's stock price, falling over 20% in pre-market trading. The company's full-year 2024 revenue reached $1.59 billion, up 19% from $1.34 billion in 2023, with a net loss of $178 million, an improvement from a $293 million loss in 2023. Fubo TV is set to merge its North American pay TV business with Walt Disney's Hulu + Live TV, aiming to create a leading streaming entity. The merger, pending shareholder and regulatory approval, will be managed by Fubo's executive team, with Disney holding a majority stake. Additionally, Fubo plans to launch a new 'Sports & Broadcasting' service by the fall of 2025, targeting sports fans with a competitive offering against other streaming bundles.




























































Positive results from the Phase 3 WAYPOINT trial in CRSwNP reinforce the epithelium as a key target for inflammatory disease treatment. #AAAAI25 ๐ Details: https://t.co/o7irfzKm9x $AMGN https://t.co/Hdww528pPD
Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps https://t.co/XQHjAA164j https://t.co/zTBjIkQntF
Presented at #AAAAI25: In patients with chronic severe rhinosinusitis and nasal polyps, tezepelumab therapy led to greater reductions in polyp size and nasal congestion and less use of surgery and glucocorticoids than placebo. Read the full WAYPOINT study results:โฆ https://t.co/vpb8PdNxJM